Brief: Amniotics Gets Positive Opinion On Orphan Designation For Pulmostem From EMA
20/11/2023 14:41
Nov 20 (Reuters) - Amniotics AB (publ) AMNI.ST :
* AMNIOTICS RECEIVES POSITIVE OPINION ON ORPHAN DESIGNATION
FOR
PULMOSTEM® FROM THE EUROPEAN MEDICINES AGENCY FOR THE TREATMENT
OF PRIMARY GRAFT DYSFUNCTION FOLLOWING LUNG TRANSPLANTATION
* EXPECTS TO START A CLINICAL STUDY EVALUATING PULMOSTEM IN
THIS
INDICATION DURING 2024.
Source text for Eikon: ID:nMFN4Zhl9X
Further company coverage: AMNI.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Amniotics AB (publ)
See all newsBrief: Swedish Companies Registration Office Authorises Magle Group, Amniotics Merger Plan
Brief: Amniotics H1 Net Revenue SEK 2.5 Million
Brief: Amniotics Gets Conditional Approval To Delist From Nasdaq First North Growth Market
Brief: Amniotics To Delist From Nasdaq First North Growth Market Upon Magle Group Merger Completion
Brief: Magle Chemoswed, Amniotics Adopt Merger Plan